FY2024 EPS Estimates for BioNTech Decreased by Analyst

BioNTech SE (NASDAQ:BNTX - Free Report) - Equities research analysts at Leerink Partnrs decreased their FY2024 EPS estimates for shares of BioNTech in a research note issued on Wednesday, November 13th. Leerink Partnrs analyst D. Graybosch now forecasts that the company will post earnings per share of ($3.79) for the year, down from their prior forecast of ($1.84). The consensus estimate for BioNTech's current full-year earnings is ($3.68) per share. Leerink Partnrs also issued estimates for BioNTech's Q4 2024 earnings at $0.42 EPS, Q1 2025 earnings at ($1.81) EPS, Q2 2025 earnings at ($2.30) EPS, Q3 2025 earnings at $2.20 EPS, Q4 2025 earnings at $1.85 EPS, FY2025 earnings at ($0.07) EPS, FY2026 earnings at ($0.41) EPS, FY2027 earnings at ($2.04) EPS and FY2028 earnings at ($1.09) EPS.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.81 EPS for the quarter, topping analysts' consensus estimates of ($1.26) by $2.07. The company had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company's quarterly revenue was up 38.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.73 EPS.

A number of other research analysts have also weighed in on BNTX. Jefferies Financial Group raised shares of BioNTech from a "hold" rating to a "buy" rating and boosted their target price for the stock from $96.00 to $150.00 in a research report on Tuesday, September 17th. Hsbc Global Res raised BioNTech from a "hold" rating to a "strong-buy" rating in a research note on Friday, August 2nd. Canaccord Genuity Group reiterated a "buy" rating and set a $171.00 price objective on shares of BioNTech in a report on Thursday. HSBC increased their target price on shares of BioNTech from $97.00 to $136.00 and gave the stock a "buy" rating in a report on Monday, October 7th. Finally, Bank of America increased their price objective on BioNTech from $125.00 to $150.00 and gave the company a "buy" rating in a report on Monday, September 16th. Four research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $137.54.

BioNTech Stock Up 2.2 %

Shares of NASDAQ BNTX traded up $2.15 during mid-day trading on Monday, reaching $101.87. The company had a trading volume of 1,286,306 shares, compared to its average volume of 807,007. The stock has a fifty day moving average of $113.57 and a two-hundred day moving average of $97.36. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. BioNTech has a 12-month low of $76.53 and a 12-month high of $131.49. The company has a market capitalization of $24.42 billion, a price-to-earnings ratio of -48.51 and a beta of 0.26.

Hedge Funds Weigh In On BioNTech

A number of hedge funds have recently bought and sold shares of BNTX. Candriam S.C.A. grew its holdings in shares of BioNTech by 261.2% in the second quarter. Candriam S.C.A. now owns 578,998 shares of the company's stock worth $46,526,000 after acquiring an additional 418,695 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in shares of BioNTech by 63.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 18,939 shares of the company's stock valued at $2,249,000 after purchasing an additional 7,340 shares during the last quarter. Baillie Gifford & Co. increased its position in BioNTech by 0.4% in the third quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company's stock worth $986,750,000 after purchasing an additional 31,773 shares during the last quarter. Discovery Capital Management LLC CT purchased a new position in shares of BioNTech in the 2nd quarter worth approximately $2,467,000. Finally, Deerfield Management Company L.P. Series C grew its holdings in BioNTech by 4.3% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 594,000 shares of the company's stock valued at $47,734,000 after purchasing an additional 24,426 shares during the last quarter. Institutional investors own 15.52% of the company's stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.